Skip to main navigation
Skip to main content

 

Skip to content
  • HOME
  • ABOUT
    VBL
    • COMPANY OVERVIEW
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
    • ADVISORY BOARDS
  • CANCER
    PROGRAMS
    • OVERVIEW
    • CANCER PLATFORM
    • CANCER PIPELINE
  • INFLAMMATION
    PROGRAMS
    • OVERVIEW
    • INFLAMMATORY PLATFORM
    • INFLAMMATORY PIPELINE
  • VB-600
    PLATFORM
    • OVERVIEW
    • TARGETING MOSPD2 FOR INFLAMMATION
    • TARGETING MOSPD2 FOR CANCER
    • PUBLICATIONS
  • FOR
    PATIENTS
    • OVERVIEW
    • CLINICAL TRIALS
    • GLIOBASTOMA MULTIFORME
    • DIFFERENTIATED THYROID CANCER
    • OVARIAN CANCER
    • PSORIASIS
    • ULCERATIVE COLITIS
  • FOR
    PHYSICIANS
    • OVERVIEW
    • CLINICAL TRIALS
    • PHYSICIAN INQUIRIES
  • INVESTOR
    RELATIONS
    • IR HOMEPAGE
    • PRESS RELEASES
    • EVENTS AND PRESENTATIONS
    • STOCK INFORMATION
    • ANALYST COVERAGE
    • CORPORATE GOVERNANCE
    • SEC FILINGS
    • FINANCIAL INFORMATION
    • INVESTOR FAQ & CONTACTS
  • NEWS
    ROOM
About_VBL_2

Investor Relations

  • IR HOMEPAGE
  • PRESS RELEASES
  • EVENTS AND PRESENTATIONS
    • Upcoming Events
    • Archived Events
    • Presentations
  • STOCK INFORMATION
  • ANALYST COVERAGE
  • SEC FILINGS
  • CORPORATE GOVERNANCE
  • INVESTOR FAQ & CONTACTS

Investor Relations

Event Calendar - Upcoming Events

Upcoming Events | Archived Events | Presentations

August 13, 2019 8:30 AM EDT

VBL Therapeutics Q2 2019 Financial Results

Add to Outlook
Add to Google Calendar
  • Print Page
  • RSS
  • E-mail Alerts
  • Investor Contacts
Copyright © 2014 VBL All rights reserved
  • TERMS AND CONDITIONS
  • PRIVACY
  • CONTACT US
Design by: Berliner Design   |  Site by: foothold-systems
Print Friendly